Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Metabolic Disorder Therapeutics
... at a CAGR of 6.9% over the analysis period 2024-2030. Diabetes Therapeutics, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$91.9 Billion by the end of ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Hyaluronidase
... 8.2% over the analysis period 2024-2030. Animal-Derived Hyaluronidase, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth ... Read More
-
Infectious Disease Therapeutics
... at a CAGR of 7.1% over the analysis period 2024-2030. HIV Therapeutics, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$113.7 Billion by the end of ... Read More
-
Acute Repetitive Seizures
... at a CAGR of 45.4% over the analysis period 2024-2030. Diastat Rectal Gel, one of the segments analyzed in the report, is expected to record a 46.9% CAGR and reach US$8.4 Billion by the end ... Read More
-
Amyloidosis Treatment
... CAGR of 6.8% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.7 Billion by the end of the analysis period. ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Women's Health Therapeutics
... at a CAGR of 12.9% over the analysis period 2024-2030. Postmenopausal Osteoporosis Application, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$18.1 Billion by the end ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
Biosimulation Technology
... CAGR of 15.6% over the analysis period 2024-2030. Biosimulation Software, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$5.7 Billion by the end of the analysis ... Read More
-
Endometriosis Drugs
... CAGR of 3.0% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.2 Billion by the end of the analysis ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. HCS Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the ... Read More
-
Myeloproliferative Disorders Drugs
... at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic Myelogenous Leukemia (CML) Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application (Diagnostics (Clinical, PoC), Research (Proteomic, Genomics, Cell), Therapeutics (Drug Delivery, Wearables)), End User- Global Forecast to 2029
... to a number of important factors. The growing requirement for point-of-care diagnostics is one of an important factor. The necessity for fast and accurate diagnosis has risen due to the increase in chronic diseases like ... Read More
-
Idiopathic Pulmonary Fibrosis
... at a CAGR of 5.7% over the analysis period 2024-2030. Pirfenidone, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.8 Billion by the end of the ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Fragment-based Drug Discovery
... at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening Technology, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end ... Read More
-
Glaucoma Therapeutics
... CAGR of 3.5% over the analysis period 2024-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.9 Billion by the end of the analysis ... Read More
-
Rheumatology Therapeutics
... CAGR of 3.2% over the analysis period 2024-2030. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$51.3 Billion by the end ... Read More
-
Scleroderma Diagnostics and Therapeutics
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Localized Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.9 Billion by the ... Read More
-
Influenza Medication
... CAGR of 1.9% over the analysis period 2024-2030. Zanamivir, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$123.9 Million by the end of the analysis period. ... Read More
-
Liver Diseases Treatment
... at a CAGR of 10.5% over the analysis period 2024-2030. Anti-Rejection Drugs/Immunosupressants, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$6.3 Billion by the end of ... Read More
-
Vitiligo Therapeutics
... CAGR of 4.0% over the analysis period 2024-2030. Topical Therapeutics, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.2 Billion by the end of the analysis ... Read More
Research Assistance
